Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T18:21:49.575Z.
Calculation as of: 2026-10-06T18:21:49.575Z.
Quote observation: 2026-10-06T18:20:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 76fc2c3b696fe1037033af5d10d354cd3b8573abd6cfebee9ff2ae185940ee40
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$2.44B
EV/EBIT Ratio
N/A
TTM Avg
30.85x
3Y Avg
58.02x
5Y Avg
40.57x
Market Cap
$2.40B
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.40B
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.36B
EV/EBIT Ratio
11.23x
TTM Avg
17.19x
3Y Avg
119.55x
5Y Avg
119.55x
Market Cap
$2.35B
EV/EBIT Ratio
13.00x
TTM Avg
116.99x
3Y Avg
116.99x
5Y Avg
116.99x
Market Cap
$2.33B
EV/EBIT Ratio
25.50x
TTM Avg
21.29x
3Y Avg
26.27x
5Y Avg
25.42x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Disc Medicine, Inc. (IRON) | $2.42B | N/A | N/A | N/A | N/A |
| Supernus Pharmaceuticals, Inc. (SUPN)vs › | $2.44B | N/A | 30.85x | 58.02x | 40.57x |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | N/A | N/A | N/A | N/A |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.40B | N/A | N/A | N/A | N/A |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.37B | N/A | N/A | N/A | N/A |
| ADMA Biologics, Inc. (ADMA)vs › | $2.36B | 11.23x | 17.19x | 119.55x | 119.55x |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.34B | N/A | N/A | N/A | N/A |
| Liquidia Corporation (LQDA)vs › | $2.35B | 13.00x | 116.99x | 116.99x | 116.99x |
| UFP Technologies, Inc. (UFPT)vs › | $2.33B | 25.50x | 21.29x | 26.27x | 25.42x |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.52B | N/A | 3.68x | 3.68x | 3.68x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
